Skip to main content

Table 4 Logistic regression analyses predicting the probability of prostate cancer

From: Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study

Predictors AUC of individual predictor variable (95% CI);
P value*
Bivariate analysis
OR(95%CI);
P value
Multivariate analysis
Base model **
OR (95%CI); P value
Base model + %p2PSA
OR (95%CI); P value
Base model + PHI
OR (95%CI); P value
Age 0.66
(0.57–0.74) 0.470
1.077
(1.03–1.13); 0.002
1.063
(1.01–1.12); 0.014
1.070
(1.02–1.13); 0.011
1.068
(1.01–1.13); 0.013
tPSA, ng/mL 0.63
(0.54 − 0.71) -
1.100
(1.04–1.16); 0.001
1.064
(0.96–1.18); 0.252
1.049
(0.95 − 1.16); 0.335
1.013
(0.93–1.10); 0.761
fPSA 0.57
(0.48–0.65) 0.117
1.543
(1.06–2.25); 0.024
1.036
(0.51–2.10); 0.921
1.012
(0.52–1.97); 0.971
0.886
(0.48–1.65); 0.701
%fPSA 0.69
(0.61–0.77) 0.203
0.927
(0.88–0.98); 0.004
0.943
(0.87–1.03); 0.181
0.947
(0.87–1.03); 0.193
0.959
(0.89–1.04); 0.294
p2PSA, pg/mL 0.69
(0.60–0.76) 0.157
1.021
(1.01–1.04);
0.001
%p2PSA 0.72
(0.63–0.78) 0.109
1.708
(1.31–2.22); < 0.001
1.550
(1.18–2.04); 0.002
PHI 0.76
(0.67–0.82) 0.005
1.017
(1.01–1.02); < 0.001
1.015
(1.01–1.02); 0.002
AUC of multivariate models (95% CI); 0.736
(0.66–0.81)
< 0.001
0.793
(0.72–0.86)
< 0.001
0.796
(0.72–0.86)
< 0.001
Gain in predictive accuracy (95% CI);
P value
0.056
(− 0.0–0.11);
0.058
0.060
(0.00–0.12);
0.037
  1. AUC, area under the receiver operating characteristic curve; PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index; tPSA, total PSA; OR, odds ratio; CI, confidence interval
  2. *P value: Comparison of AUC using tPSA as standard
  3. **Base model includes age, tPSA, fPSA and %fPSA
  4. P value to be statiscally significant with bolditalics